Cargando…

Proteasome Inhibitors Suppress ErbB Family Expression through HSP90-Mediated Lysosomal Degradation

Although dual EGFR/HER2 tyrosine kinase inhibitor lapatinib has provided effective clinical benefits for HER2-positive breast cancer patients, acquired resistance to this drug remains a major concern. Thus, the development of alternative therapeutic strategies is urgently needed for patients who fai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huynh, Thanh Kieu, Ho, Chien-Yi, Tsai, Chi-Hua, Wang, Chien-Kuo, Chen, Yun-Ju, Bau, Da-Tian, Tu, Chih-Yen, Li, Tzong-Shiun, Huang, Wei-Chien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801459/ https://www.ncbi.nlm.nih.gov/pubmed/31569723 http://dx.doi.org/10.3390/ijms20194812

Ejemplares similares

Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition
por: Raja, Srikumar M., et al.
Publicado: (2016)

The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments
por: Cortese, Katia, et al.
Publicado: (2013)

Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition
por: Xu, W, et al.
Publicado: (2007)

Hsp90 Chaperones Bluetongue Virus Proteins and Prevents Proteasomal Degradation
por: Mohl, Bjorn-Patrick, et al.
Publicado: (2019)

A way to invade: A story of ErbB2 and lysosomes
por: Rafn, Bo, et al.
Publicado: (2012)

Regulation of ErbB2 Receptor Status by the Proteasomal DUB POH1
por: Liu, Han, et al.
Publicado: (2009)

HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3
por: Chen, Jhen-Yu, et al.
Publicado: (2015)

Corrigendum to “Epidermal Growth Factor Cytoplasmic Domain Affects ErbB Protein Degradation by the Lysosomal and Ubiquitin–Proteasome Pathway in Human Cancer Cells” [Neoplasia 14 (2012) 396–409]
por: Glogowska, Aleksandra, et al.
Publicado: (2017)

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)

Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells
por: Castagnola, Patrizio, et al.
Publicado: (2016)

Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4
por: Sutherland, Robert L
Publicado: (2011)

Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes
por: ALONSO, Juan Manuel Fernández
Publicado: (2005)

ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
por: Alvarado, Diego, et al.
Publicado: (2017)

DNAJB12 and Hsp70 Mediate Triage of Misfolded Membrane Proteins for Proteasomal versus Lysosomal Degradation
por: Kennedy, Andrew, et al.
Publicado: (2022)

Proliferation of Colorectal Cancer Is Promoted by Two Signaling Transduction Expression Patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK
por: Yao, Yong-Liang, et al.
Publicado: (2013)

HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer
por: Schulz, R, et al.
Publicado: (2014)

Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB.
por: Aasland, R., et al.
Publicado: (1988)

Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2018)

Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2016)

A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016)

The Role of ErbB Receptors in Infection
por: Ho, Jemima, et al.
Publicado: (2017)

FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion
por: Benlimame, Naciba, et al.
Publicado: (2005)

ErbB1 and ErbB3 co-over expression as a prognostic factor in gastric cancer
por: Moghbeli, Meysam, et al.
Publicado: (2019)

The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer
por: Zhang, Jinrui, et al.
Publicado: (2020)

Capsaicin binds the N-terminus of Hsp90, induces lysosomal degradation of Hsp70, and enhances the anti-tumor effects of 17-AAG (Tanespimycin)
por: Patwardhan, Chaitanya A., et al.
Publicado: (2023)

erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification.
por: Colomer, R., et al.
Publicado: (1994)

Betacellulin-Induced Beta Cell Proliferation and Regeneration Is Mediated by Activation of ErbB-1 and ErbB-2 Receptors
por: Oh, Yoon Sin, et al.
Publicado: (2011)

Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting
por: Singer, Josef, et al.
Publicado: (2012)

Quantitative Analysis of ErbB1 and ErbB2 Genes Amplification by a High Performance Liquid Chromatography
por: Rasti, Mozhgan, et al.
Publicado: (2014)

Effects of ErbB2 Overexpression on the Proteome and ErbB Ligand-specific Phosphosignaling in Mammary Luminal Epithelial Cells
por: Worthington, Jenny, et al.
Publicado: (2017)

Development of ErbB2-Targeting Liposomes for Enhancing Drug Delivery to ErbB2-Positive Breast Cancer
por: Ueno, Sho, et al.
Publicado: (2020)

DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells
por: Bi, Yanli, et al.
Publicado: (2021)

IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome
por: Thompson, Leslie Michels, et al.
Publicado: (2009)

The interactome of human EGF/ErbB receptors
por: Uetz, Peter, et al.
Publicado: (2006)

Inhibition of HSP90β Improves Lipid Disorders by Promoting Mature SREBPs Degradation via the Ubiquitin-proteasome System
por: Zheng, Zu-Guo, et al.
Publicado: (2019)

Fulvestrant-induced expression of erbB3 and erbB4 sensitizes ER-positive breast cancer cells to heregulins
por: Hutcheson, IR, et al.
Publicado: (2010)

Spinal nerve injury causes upregulation of ErbB2 and ErbB3 receptors in rat dorsal root ganglia
por: Mizobuchi, Satoshi, et al.
Publicado: (2013)

ErbB3-binding protein EBP1 decreases ErbB2 levels via a transcriptional mechanism
por: GHOSH, ARUNDHATI, et al.
Publicado: (2012)

Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer
por: Ghasemi, R, et al.
Publicado: (2014)

Melatonin upregulates ErbB1 and ErbB4, two primary implantation receptors, in pre-implantation mouse embryos
por: Moshkdanian, Ghazaleh, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5qdtfp69tba70ppprbmmdkn57k